Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysisKazem Rahimi, Takayoshi Ohkubo, Barry R. Davis et al.|The Lancet|2021Cited by 997
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trialOfri Mosenzon, Itamar Raz, Stephen D. Wiviott et al.|The Lancet Diabetes & Endocrinology|2019Cited by 673
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristicsDavid C. Wheeler, Hiddo J.L. Heerspink, Bergur V. Stefánsson et al.|Nephrology Dialysis Transplantation|2020Cited by 189
Diabetic Proteinuria Revisited: Updated Physiologic PerspectivesSamuel N. Heyman, Zaid Abassi, Itamar Raz et al.|Cells|2022Cited by 51